BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34595844)

  • 1. Association of radiation dose intensity with overall survival in patients with distant metastases.
    Kao J; Farrugia MK; Frontario S; Zucker A; Copel E; Loscalzo J; Sangal A; Darakchiev B; Singh A; Missios S
    Cancer Med; 2021 Nov; 10(22):7934-7942. PubMed ID: 34595844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
    Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
    J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Survival Prognostication in Patients With Metastatic Cancer Through Clinical Judgment.
    Kao J; Zucker A; Urso M; Karwowski P; Jain N; Jain S; Bustamante G; Lugo D; Rowland L
    Anticancer Res; 2022 Mar; 42(3):1397-1401. PubMed ID: 35220232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated stereotactic radiotherapy of limited brain metastases: a single-centre individualized treatment approach.
    Märtens B; Janssen S; Werner M; Frühauf J; Christiansen H; Bremer M; Steinmann D
    BMC Cancer; 2012 Oct; 12():497. PubMed ID: 23098039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?
    Nieder C; Yobuta R; Mannsåker B; Dalhaug A
    In Vivo; 2018; 32(2):331-336. PubMed ID: 29475917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.
    Hasan S; Renz P; Turrisi A; Colonias A; Finley G; Wegner RE
    Lung Cancer; 2018 Oct; 124():283-290. PubMed ID: 30268474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy.
    Sanghvi SM; Lischalk JW; Cai L; Collins S; Nair M; Collins B; Unger K
    Radiat Oncol; 2017 Feb; 12(1):43. PubMed ID: 28245881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology.
    Kao J; Gold KD; Zarrili G; Copel E; Silverman AJ; Ramsaran SS; Yens D; Ryu S
    PLoS One; 2015; 10(4):e0124329. PubMed ID: 25894552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
    Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
    Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
    Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
    Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.
    Sultanem K; Shu HK; Xia P; Akazawa C; Quivey JM; Verhey LJ; Fu KK
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):711-22. PubMed ID: 11020568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
    Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
    JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis.
    McDuff SGR; Remillard KA; Zheng H; Raldow AC; Wo JY; Eyler CE; Drapek LC; Goyal L; Blaszkowsky LS; Clark JW; Allen JN; Parikh AR; Ryan DP; Ferrone CR; Tanabe KK; Wolfgang JA; Zhu AX; Hong TS
    Pract Radiat Oncol; 2018; 8(6):414-421. PubMed ID: 29937235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma.
    Sebastian NT; Tan Y; Miller ED; Williams TM; Noonan AM; Hays JL; Abdel-Misih S; Diaz DA
    JAMA Netw Open; 2019 Sep; 2(9):e1911154. PubMed ID: 31517963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
    Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.